| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Heavy chain antibodies (4P94 and 4P41) which bind with the Loop1 and Loop2 of the OprM (consisting a multi-drug resistant pump) existing outside of the outer membrane, have been isolated by using the M13-phage display method, respectively. The mono, di and trimers of the Heavy chain antibodies were designed and produced in E. coli. Those antibodies were purified with Protein A, His-Trap and Endotoxin-Trap columns. When pseudomonas aeruginosa (drug sensitive PAO-1, multi-drug resistant nalB and NCGM2.S1) were treated with colistin together with those antibodies, MIC (minimum growth-inhibition concentration) of the colistin decreased to a half to one fourth of the MIC with colistin alone. The side effects for the colistin-treatment in the clinical setting were known to be kidney and neurological failures. Co-treatment of colistin with those antibodies is anticipated to reduce the side effects.
|
